Tudobest 300mg Tablet

The doctor determines the dosage and duration of treatment with Tudobest 300mg Tablet as per the patient's health condition. It is advised to take this medicine after consulting your healthcare expert. This medicine should be taken orally at the same time every day. Please do not crush or chew the medicine and eat it as a whole with water.

The active ingredient of Tudobest is Tenofovir Disoproxil Fumarate, which belongs to the drug class of nucleoside reverse transcriptase inhibitors (NRTIs). It works by inhibiting the replication process of HIV infection. It improves the immune system of the patient to fight against infection, controls the virus production, reduces the viral load in the body and slows down the growth of this disease, and works on overall health.

It is advised not to miss any scheduled dosage of the Tudobest 300mg. In case you miss a dose, consult your doctor immediately.

Don't overdose to compensate for the missed one. Contact your doctor or any healthcare provider and seek medical attention immediately in such cases.

It is advised to use effective birth control methods to avoid pregnancy. Some drugs can cause birth defects, miscarriage, or death to an unborn baby if the mother or father is using this medicine. Moreover, this medicine may pass to the unborn baby.

Consult your doctor if you observe symptoms such as abdominal pain, loss of appetite, dark urine, or yellowing of the eyes or skin. These symptoms indicate the presence of Jaundice in the body.

It is advised to tell your doctor about all medicines (multivitamins, herbal supplements) you're taking currently before starting your course with Tudobest 300mg. There are chances that many drugs can interact, and some drugs should not be used together.

Inform your healthcare expert in case of a history of severe blood infection, active tuberculosis, liver problems, or any serious health disorder.

1. Nelson, M. R., Katlama, C., Montaner, J. S., Cooper, D. A., Gazzard, B., Clotet, B., ... & Rooney, J. F. (2007). The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. Aids, 21(10), 1273-1281.
2. Lyseng-Williamson, K. A., Reynolds, N. A., & Plosker, G. L. (2005). Tenofovir disoproxil fumarate: a review of its use in the management of HIV infection. Drugs, 65(3), 413-432.
3. Kearney, B. P., Flaherty, J. F., & Shah, J. (2004). Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clinical pharmacokinetics, 43(9), 595-612.
4. Wassner, C., Bradley, N., & Lee, Y. (2020). A review and clinical understanding of tenofovir: tenofovir disoproxil fumarate versus tenofovir alafenamide. Journal of the International Association of Providers of AIDS Care (JIAPAC), 19, 2325958220919231.
5. Gallant, J. E., & Deresinski, S. (2003). Tenofovir disoproxil fumarate. Clinical Infectious Diseases, 37(7), 944-950.